TBUFF Pengajuan SEC - Tribute Pharmaceuticals Canada Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1159019

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tribute Pharmaceuticals Canada Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

February 16, 2016	SC 13G	TBUFF / Tribute Pharmaceuticals Canada Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 12, 2016	15-12G	Tribute Pharmaceuticals Canada CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION 15-12G 1 tbuff1512g.htm CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Num
February 11, 2016	EX-10.4	RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY tbuffex104.htm Exhibit 10.4 RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this ?Release?) is made as of February 5th , 2016 (?Effective Date?) by and between SWK FUNDING LLC., a Delaware limited liability company, in its capacity as collateral agent for the Lenders party to the Credit Agreement (defined below) (in such capacity, ?
February 11, 2016	EX-3.1	EX-3.1 tbuffex31.htm Exhibit 3.1
February 11, 2016	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 5, 2016 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisd
February 11, 2016	EX-10.3	RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY tbuffex103.htm Exhibit 10.1 RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this ?Release?) is made as of the 5th day of February, 2016, by SWK FUNDING LLC, a Delaware limited liability company (?Assignor?) in favor of TRIBUTE PHARMACEUTICALS CANADA, INC., TRIBUTE PHARMACEUTICALS US INC., and TRIBUTE PHARMACEUTICALS INTERNATIONAL, I
February 5, 2016	POS AM	Tribute Pharmaceuticals Canada POST-EFFECTIVE AMENDMENT tbuffposam.htm As filed with the Securities and Exchange Commission on February 4, 2016 Registration No. 333-187927 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRIBUTE PHARMACEUTICALS CANADA INC. (Exact name of registrant as specified in its charter) Ontario 2834 Not Appli
February 5, 2016	POS AM	Tribute Pharmaceuticals Canada POST-EFFECTIVE AMENDMENT tbuffposam.htm As filed with the Securities and Exchange Commission on February 4, 2016 Registration No. 333-170459 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRIBUTE PHARMACEUTICALS CANADA INC. (Exact name of registrant as specified in its charter) Ontario 2834 Not Appli
February 5, 2016	POS AM	Tribute Pharmaceuticals Canada POST-EFFECTIVE AMENDMENT tbuffposam.htm As filed with the Securities and Exchange Commission on February 4, 2016 Registration No. 333-197817 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRIBUTE PHARMACEUTICALS CANADA INC. (Exact name of registrant as specified in its charter) Ontario 2834 Not Appli
February 5, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 5, 2016 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisd
February 5, 2016	EX-99.1	POZEN AND TRIBUTE COMBINE TO CREATE ARALEZ PHARMACEUTICALS INC. -Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio- -Canadian Domicile Provides Compelling Platform for Growth with Competitive Structure tbuffex991.htm Exhibit 99.1 POZEN AND TRIBUTE COMBINE TO CREATE ARALEZ PHARMACEUTICALS INC. -Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio- -Canadian Domicile Provides Compelling Platform for Growth with Competitive Structure- -US$350 Million Capital Commitment from Deerfield-Led Syndicate- MILTON, Ontario ? February 5, 2016 ? Aralez Pharmaceuti
February 1, 2016	EX-99.1	TRIBUTE ANNOUNCES RESULTS OF SHAREHOLDER VOTE tbuffex991.htm EXHIBIT 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. TRIBUTE ANNOUNCES RESULTS OF SHAREHOLDER VOTE MILTON, ONTARIO - February 1, 2016 - Tribute Pharmaceuticals Canada Inc. (TSXV:TRX or OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in
February 1, 2016	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 1, 2016 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisd
January 29, 2016	10-Q/A	Quarterly Report - AMENDMENT TO QUARTERLY REPORT tbuff10a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q/A Amendment No. 1 ??????? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2015 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to ??????
January 21, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 21, 2016 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisd
January 21, 2016	EX-99.1	Leading Independent Advisors Recommend that Tribute Shareholders Vote FOR the Transaction tbuffex991.htm Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Leading Independent Advisors Recommend that Tribute Shareholders Vote FOR the Transaction MILTON, ONTARIO - 1/21/16 - Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX) (OTCQX International: TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licens
January 11, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 11, 2016 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisdiction of in
January 11, 2016	EX-99.1	Tribute Mails Materials In Connection with Special Meeting of Shareholders to Approve Transaction with Pozen and Encourages Shareholders to Vote tbuffex991.htm Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Mails Materials In Connection with Special Meeting of Shareholders to Approve Transaction with Pozen and Encourages Shareholders to Vote MILTON, ONTARIO - 1/11/16 - Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX) (OTCQX International: TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical
January 11, 2016	EX-99.2	TRIBUTE PHARMACEUTICALS CANADA INC. ARALEZ PHARMACEUTICALS INC. ARLZ CA ACQUISITION CORP., to be a wholly-owned subsidiary of Aralez Pharmaceuticals Inc. NOTICE OF SPECIAL MEETING MANAGEMENT INFORMATION CIRCULAR THE SPECIAL MEETING OF SHAREHOLDERS OF tbuffex992.htm Exhibit 99.2 None of the Canadian securities regulatory authorities nor the United States Securities and Exchange Commission nor any state securities commission has approved or disapproved of the proposed Transaction involving Tribute Pharmaceutical Canada Inc., Aralez Pharmaceuticals Inc., ARLZ US Acquisition II Corp., ARLZ CA Acquisition Corp. and POZEN Inc. or passed upon the mer
January 4, 2016	EX-99.1	Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia® Use in Migraine Treatment tbuffex991.htm Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia? Use in Migraine Treatment MILTON, ONTARIO - (Marketwired) - 01/04/16 - Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute" or the "Company"), a Canadian pharmaceutical company with a primary focus
January 4, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 4, 2016 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisdi
December 28, 2015	EX-99.1	TRIBUTE SCHEDULES SPECIAL SHAREHOLDER MEETING FOR FEBRUARY 1, 2016 tbuffex991.htm Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. TRIBUTE SCHEDULES SPECIAL SHAREHOLDER MEETING FOR FEBRUARY 1, 2016 MILTON, ONTARIO ? December 28, 2015 - Tribute Pharmaceuticals Canada Inc. (TSXV:TRX or OTCQX:TBUFF) (?Tribute? or the ?Company?), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of h
December 28, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 tbuff8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 28, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable
December 8, 2015	EX-10.1	ARTICLE 1 tbuffex101.htm Exhibit 10.1 SECOND AMENDED AND RESTATED FACILITY AGREEMENT This SECOND AMENDED AND RESTATED FACILITY AGREEMENT (this ?Agreement?), dated as of December 7, 2015, by and among Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada (?Parent?), POZEN Inc., a corporation formed under the laws of the State of Delaware (?Pozen?), Tribu
December 8, 2015	EX-2.2	AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT tbuffex21.htm Exhibit 2.2 AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT This AMENDMENT NO. 2 (this ?Amendment?) to the Agreement and Plan of Merger and Arrangement is made as of December 7, 2015, by and among Tribute Pharmaceuticals Canada Inc., a corporation formed under the laws of the Province of Ontario, Canada (?Tribute?), Aralez Pharmaceuticals plc, a public limited company
December 8, 2015	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 7, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisd
December 8, 2015	EX-2.1	AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT tbuffex2.htm Exhibit 2.1 AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT AMENDMENT NO. 1, dated as of August 19, 2015 (this ?Amendment?), to the Agreement and Plan of Merger and Arrangement, dated as of June 8, 2015 (the ?Merger Agreement?), by and among Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario (?Tribute?), Aguono Lim
December 2, 2015	EX-1.1	ASSET PURCHASE AGREEMENT by and between TRIBUTE PHARMACEUTICALS INTERNATIONAL INC. MUTUAL PHARMACEUTICAL COMPANY, INC. SUN PHARMACEUTICAL INDUSTRIES, INC. Dated: May 21, 2015 ASSET PURCHASE AGREEMENT tbuffex11.htm Exhibit 1.1 ASSET PURCHASE AGREEMENT by and between TRIBUTE PHARMACEUTICALS INTERNATIONAL INC. and MUTUAL PHARMACEUTICAL COMPANY, INC. and SUN PHARMACEUTICAL INDUSTRIES, INC. Dated: May 21, 2015 ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of this 21st of May, 2015 (the ?Effective Date?), by and between Tribute Pharmaceuticals
December 2, 2015	8-K/A	Financial Statements and Exhibits tbuff8ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 21, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (Stat
November 23, 2015	EX-99.1	POZEN AND TRIBUTE PROVIDE UPDATE ON PENDING COMBINATION TRANSACTIONS -POZEN and Tribute Evaluating Canadian Domicile for Aralez Pharmaceuticals- tbuffex991.htm Exhibit 99.1 POZEN AND TRIBUTE PROVIDE UPDATE ON PENDING COMBINATION TRANSACTIONS -POZEN and Tribute Evaluating Canadian Domicile for Aralez Pharmaceuticals- CHAPEL HILL, NC and MILTON, Ontario ? November 23, 2015 ? POZEN Inc. (?POZEN?) (NASDAQ: POZN) and Tribute Pharmaceuticals Canada Inc. (?Tribute?) (TSX VENTURE:TRX) (OTCQX International:TBUFF) today provided an update on their p
November 23, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 tbuff8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 23, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable
November 9, 2015	EX-99.1	TRIBUTE PHARMACEUTICALS CANADA INC. ARALEZ PHARMACEUTICALS LIMITED ARLZ CA ACQUISITION CORP., a wholly-owned subsidiary of Aralez Pharmaceuticals Limited NOTICE OF SPECIAL MEETING MANAGEMENT PROXY CIRCULAR THE SPECIAL MEETING OF SHAREHOLDERS OF TRIBU tbuffex991.htm Exhibit 99.1 None of the Canadian securities regulatory authorities nor the United States Securities and Exchange Commission nor any state securities commission has approved or disapproved of the proposed Transaction involving Tribute Pharmaceutical Canada Inc., Aralez Pharmaceuticals Limited (formerly Aguono Limited), Aralez Pharmaceuticals Holdings Limited (formerly Trafwell Limit
November 9, 2015	EX-3.1	CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Rob Harris, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Tribute Pharmaceuticals Canada Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
November 9, 2015	EX-99.1	Tribute Announces Third Quarter 2015 Results -Revenue Up 133%, EBITDA Up 281% over Comparative Period- tbuffex991.htm Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Announces Third Quarter 2015 Results -Revenue Up 133%, EBITDA Up 281% over Comparative Period- MILTON, ONTARIO ? November 9, 2015 - Tribute Pharmaceuticals Canada Inc. (TSXV:TRX or OTCQX International:TBUFF) ("Tribute" or the "Company"), a diversified healthcare company with a primary focus on the acquisi
November 9, 2015	EX-99.1	POZEN AND TRIBUTE ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT ON FORM S-4 -POZEN Schedules Stockholder Meeting for December 10, 2015 -Tribute Schedules Shareholder Meeting for December 9, 2015 tbuffex991.htm Exhibit 99.1 POZEN AND TRIBUTE ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT ON FORM S-4 -POZEN Schedules Stockholder Meeting for December 10, 2015 -Tribute Schedules Shareholder Meeting for December 9, 2015 CHAPEL HILL, NC and MILTON, ON ? November 6, 2015 ? POZEN Inc. (?POZEN?) (NASDAQ: POZN) and Tribute Pharmaceuticals Canada Inc. (?Tribute?) (TSXV:TRX or OTCQX International:T
November 9, 2015	8-K	Tribute Pharmaceuticals Canada CURRENT REPORT (Current Report/Significant Event) tbuff_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other juris
November 9, 2015	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2015 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to ——————— TRIBUTE PHARMACEUTICALS
November 9, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K 1 tbuff8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (
November 9, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 9, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisd
November 6, 2015	EX-99.1	POZEN AND TRIBUTE ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT ON FORM S-4 -POZEN Schedules Stockholder Meeting for December 10, 2015 -Tribute Schedules Shareholder Meeting for December 9, 2015 Exhibit 99.1 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934, as amended Filing Person: POZEN Inc. Subject Company: Tribute Pharmaceuticals Canada Inc. Commission File No.: 000-31198 POZEN AND TRIBUTE ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT ON FORM S-4 -POZEN Schedules Stockholder Meetin
November 6, 2015	425	Pozen 8-K (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number
October 30, 2015	EX-99.3	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS tbuffex993.htm Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial information has been prepared to illustrate the effects of the asset purchase agreement with Novartis AG and Novartis Pharma AG (collectively, ?Novartis? and together with the company, the ?Parties?), pursuant to which the Company acquired from Nova
October 30, 2015	8-K	Financial Statements and Exhibits tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 3) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 2, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (St
October 29, 2015	EX-99.2	Fiorinal®, Fiorinal® C, Visken® and Viskazide® Product Lines of Novartis Group Statements of Revenue and Related Expenses (in US Dollars) For the Nine Months ended September 30, 2014 and the Year ended December 31, 2013 tbuffex992.htm Exhibit 99.2 Fiorinal?, Fiorinal? C, Visken? and Viskazide? Product Lines of Novartis Group Statements of Revenue and Related Expenses (in US Dollars) For the Nine Months ended September 30, 2014 and the Year ended December 31, 2013 Independent Auditor?s Report To: The Board of Directors and Management of Novartis Pharma AG We have audited the accompanying Statements of Revenue and
October 29, 2015	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 2, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other
October 29, 2015	EX-99.3	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS tbuffex993.htm Exhibit 99.3 This information and PricewaterhouseCoopers LLP?s (?PwC?) services (collectively, ?Information?) are confidential and access, use and distribution are restricted. If you are not PwC?s client or otherwise authorized by PwC and its client, you may not access or use the Information. PwC performed and prepared the Information at client?s direction and exclusively for client
August 25, 2015	8-K/A	Tribute Pharmaceuticals Canada CURRENT REPORT AMENDMENT (Current Report/Significant Event) tbuff8ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 3) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 16, 2015 Tribute Pharmaceuticals Canada Inc. (Exact Name of Registrant as Specified in its Charter) Ontario, Canada 000-31198 Not Applicable (Sta
August 25, 2015	EX-4.1	UNSECURED CONVERTIBLE PROMISSORY NOTE tbuffex41.htm Exhibit 4.1 EXHIBIT B UNSECURED CONVERTIBLE PROMISSORY NOTE Cdn. $5,000,000 Due: June 16, 2016 ARTICLE 1 PRINCIPAL AND PAYMENT Section 1.1 Principal Sum and Repayment. For value received Tribute Pharmaceuticals Canada Inc. (the ?Corporation?), a corporation incorporated under the laws of Ontario, having its head office at the address set out in Section 4.2 hereof, shall pay to the or
August 25, 2015	EX-1.1	SHARE PURCHASE AGREEMENT TRIBUTE PHARMACEUTICALS CANADA INC. PARDEEP NIJHAWAN NIDHI NIJHAWAN June 16, 2015 TABLE OF CONTENTS tbuff_ex11.htm Exhibit 1.1 SHARE PURCHASE AGREEMENT BETWEEN TRIBUTE PHARMACEUTICALS CANADA INC. AND PARDEEP NIJHAWAN AND NIDHI NIJHAWAN June 16, 2015 TABLE OF CONTENTS Article 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Knowledge 7 1.3 Currency 7 1.4 Governing Law 7 1.5 Interpretation Not Affected by Headings 7 1.6 Number and Gender 7 1.7 Time of Essence 7 1.8 Severability 7 1.9 Accounting Terms 7 1.
August 17, 2015	8-K	Tribute Pharmaceuticals Canada CURRENT REPORT (Current Report/Significant Event) tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisdi
August 17, 2015	EX-99.1	Tribute Pharmaceuticals Announces Second Quarter 2015 Results -Revenue Up 59%, Gross Profit Up 101% over Comparative Period- tbuffex991.htm Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Announces Second Quarter 2015 Results -Revenue Up 59%, Gross Profit Up 101% over Comparative Period- MILTON, ONTARIO ? August 17, 2015 - Tribute Pharmaceuticals Canada Inc. (TSXV:TRX or OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on th
August 5, 2015	EX-99.4	UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS tbuffex994.htm EXHIBIT 99.4 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The following unaudited pro forma condensed consolidated financial statements is presented to illustrate the estimated effects of the acquisition by Tribute Pharmaceuticals Canada Inc. (?Tribute? or the ?Company?) of Medical Futures Inc. (together herein referred to as ?MFI?), (MFI, together with Tribute, a
August 5, 2015	8-K/A	Tribute Pharmaceuticals Canada CURRENT REPORT AMENDMENT (Current Report/Significant Event) tbuff8ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 16, 2015 Tribute Pharmaceuticals Canada Inc. (Exact Name of Registrant as Specified in its Charter) Ontario, Canada 001-31198 Not Applicable (State or
July 20, 2015	EX-99.3	EX-99.3 tbuffex993.htm Exhibit 99.3
July 20, 2015	8-K/A	Tribute Pharmaceuticals Canada AMENDED CURENT REPORT (Current Report/Significant Event) tbuff8ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 16, 2015 Tribute Pharmaceuticals Canada Inc. (Exact Name of Registrant as Specified in its Charter) Ontario, Canada 001-31198 Not Applicable (State or Incorporatio
July 20, 2015	EX-99.2	7 - 17 tbuffex992.htm Exhibit 99.2 MEDICAL FUTURES INC. Financial Statements Years Ended December 31, 2013 and 2014 (Expressed in Canadian dollars) MEDICAL FUTURES INC. Index to Financial Statements Years Ended December 31, 2013 and 2014 Page FINANCIAL STATEMENTS Balance Sheets 4 Statements of Operations and Retained Earnings 5 Statements of Cash Flows 6 Notes to Financial Statements 7 - 17 Page 2 of 17
June 22, 2015	EX-1.1	SHARE PURCHASE AGREEMENT TRIBUTE PHARMACEUTICALS CANADA INC. PARDEEP NIJHAWAN NIDHI NIJHAWAN June 16, 2015 TABLE OF CONTENTS tbuffex11.htm Exhibit 1.1 SHARE PURCHASE AGREEMENT BETWEEN TRIBUTE PHARMACEUTICALS CANADA INC. AND PARDEEP NIJHAWAN AND NIDHI NIJHAWAN June 16, 2015 TABLE OF CONTENTS Article 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Knowledge 7 1.3 Currency 7 1.4 Governing Law 7 1.5 Interpretation Not Affected by Headings 7 1.6 Number and Gender 7 1.7 Time of Essence 7 1.8 Severability 7 1.9 Accounting Terms 7 1.1
June 22, 2015	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 16, 2015 Tribute Pharmaceuticals Canada Inc. (Exact Name of Registrant as Specified in its Charter) Ontario, Canada 001-31198 Not Applicable (State or Incorporation)
June 22, 2015	EX-1.2	AGENCY AGREEMENT tbuffex12.htm Exhibit 1.2 AGENCY AGREEMENT June 16, 2015 Tribute Pharmaceuticals Canada Inc. 151 Steeles Avenue East Milton, Ontario L9T 1Y1 Attention: Rob Harris, President and Chief Executive Officer Dear Mr. Harris: The undersigned, KES 7 Capital Inc. (the ?Lead Agent?), Bloom Burton & Co. Ltd., Mackie Research Capital Corporation, Laurentian Bank Securities Inc. and Dundee Securities Inc. (col
June 22, 2015	EX-4.1	UNSECURED CONVERTIBLE PROMISSORY NOTE tbuffex41.htm Exhibit 4.1 EXHIBIT B UNSECURED CONVERTIBLE PROMISSORY NOTE Cdn. $5,000,000 Due: June 16, 2016 ARTICLE 1 PRINCIPAL AND PAYMENT Section 1.1 Principal Sum and Repayment. For value received Tribute Pharmaceuticals Canada Inc. (the ?Corporation?), a corporation incorporated under the laws of Ontario, having its head office at the address set out in Section 4.2 hereof, shall pay to the or
June 12, 2015	EX-2.1	AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT TRIBUTE PHARMACEUTICALS CANADA INC., AGUONO LIMITED, TRAFWELL LIMITED, ARLZ US ACQUISITION CORP., ARLZ CA ACQUISITION CORP., POZEN INC. June 8, 2015 tbuffex21.htm Exhibit 2.1 Execution Copy AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT AMONG TRIBUTE PHARMACEUTICALS CANADA INC., AGUONO LIMITED, TRAFWELL LIMITED, ARLZ US ACQUISITION CORP., ARLZ CA ACQUISITION CORP., AND POZEN INC. June 8, 2015 TABLE OF CONTENTS Page Article 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Currency 14 1.3 Interpretation Not Affected by Headings 14 1.4 Knowledge and Disclo
June 12, 2015	8-K	Tribute Pharmaceuticals Canada CURRENT REPORT (Current Report/Significant Event) tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 8, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisdicti
June 8, 2015	EX-99.1	POZEN ANNOUNCES STRATEGIC ACQUISITION OF TRIBUTE AND GROWTH CAPITAL COMMITMENT FROM LEADING HEALTHCARE SPONSORS Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular Treatments US$350 Million Capital Commitment tbuffex991.htm Exhibit 99.1 POZEN ANNOUNCES STRATEGIC ACQUISITION OF TRIBUTE AND GROWTH CAPITAL COMMITMENT FROM LEADING HEALTHCARE SPONSORS Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular Treatments US$350 Million Capital Commitment from Deerfield-Led Syndicate to Fund Commercial Launch and Pursue Strategic Acquisitions and Growth Opportunities Adrian
June 8, 2015	8-K	Tribute Pharmaceuticals Canada CURRENT REPORT (Current Report/Significant Event) tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 8, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisdicti
May 28, 2015	EX-1.1	ASSET PURCHASE AGREEMENT by and between TRIBUTE PHARMACEUTICALS INTERNATIONAL INC. MUTUAL PHARMACEUTICAL COMPANY, INC. SUN PHARMACEUTICAL INDUSTRIES, INC. Dated: May 21, 2015 ASSET PURCHASE AGREEMENT Exhibit 1.1 ASSET PURCHASE AGREEMENT by and between TRIBUTE PHARMACEUTICALS INTERNATIONAL INC. and MUTUAL PHARMACEUTICAL COMPANY, INC. and SUN PHARMACEUTICAL INDUSTRIES, INC. Dated: May 21, 2015 ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of this 21st of May, 2015 (the ?Effective Date?), by and between Tribute Pharmaceuticals International
May 28, 2015	EX-99.1	Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor® and Commercial Expansion into U.S. Market tbuffex991.htm Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor? and Commercial Expansion into U.S. Market ? William Maichle Hired as President of U.S. Operations MILTON, ONTARIO (Marketwired ? May 21, 2015) - Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX Venture: TRX) (?Tribute? or the ?Compan
May 28, 2015	EX-1.2	AGENCY AGREEMENT tbuffex12.htm Exhibit 1.2 AGENCY AGREEMENT May 21, 2015 Tribute Pharmaceuticals Canada Inc. 151 Steeles Avenue East Milton, Ontario L9T 1Y1 Attention: Rob Harris, President and Chief Executive Officer Dear Mr. Harris: The undersigned, Dundee Securities Ltd. (the ?Lead Agent?), Kes 7 Capital Inc., and Bloom Burton & Co. Ltd. (collectively with the Lead Agent, the ?Agents? and each individually an ?
May 28, 2015	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 21, 2015 Tribute Pharmaceuticals Canada Inc. (Exact Name of Registrant as Specified in its Charter) Ontario, Canada 001-31198 Not Applicable (State or Incorporation) (
May 21, 2015	EX-99.1	EX-99.1 ex991.htm Exhibit 99.1
May 21, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K 1 tbuff8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 19, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (Stat
May 21, 2015	EX-99.3	EX-99.3 ex993.htm Exhibit 99.3
May 21, 2015	EX-99.2	EX-99.2 ex992.htm Exhibit 99.2
May 21, 2015	EX-99.4	EX-99.4 ex994.htm Exhibit 99.4
May 14, 2015	8-K	Tribute Pharmaceuticals Canada CURRENT REPORT (Current Report/Significant Event) tbuff8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 001-31198 Not Applicable (State or other jurisdicti
May 14, 2015	EX-99.1	Tribute Pharmaceuticals Announces First Quarter 2015 Results -Revenue Up 60%, EBITDA Up 116% Over Comparative Period- tbuffex991.htm Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Announces First Quarter 2015 Results -Revenue Up 60%, EBITDA Up 116% Over Comparative Period- MILTON, ONTARIO ? May 12, 2015 - Tribute Pharmaceuticals Canada Inc. (TSXV:TRX or OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisit
March 24, 2015	EX-1	AGREEMENT OF JOINT FILING TRIBUTE PHARMACEUTICALS CANADA INC. COMMON SHARES Exhibit 1 AGREEMENT OF JOINT FILING TRIBUTE PHARMACEUTICALS CANADA INC. COMMON SHARES In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby confirm the agreement by and between them to the joint filing on behalf of each of them of a Statement on Schedule 13D, and any and all amendments thereto, with respect to the above referenced securities
March 24, 2015	EX-7	AMENDING AGREEMENT Exhibit 7 AMENDING AGREEMENT THIS AMENDING AGREEMENT dated effective the 6th day of February, 2014.
March 24, 2015	SC 13D	TBUFF / Tribute Pharmaceuticals Canada Inc. / Elora Financial Management Inc. - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Tribute Pharmaceuticals Canada Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 89609J106 (CUSIP Number) Scott Langille 151 Steeles Avenue, East Milton, Ontario, Canada L9T 1Y1 (519) 434-1540 (Name, address and telephone number of person
March 18, 2015	SC 13D	TBUFF / Tribute Pharmaceuticals Canada Inc. / Harris Robert Paul - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Tribute Pharmaceuticals Canada Inc.
March 16, 2015	SC 13D/A	TBUFF / Tribute Pharmaceuticals Canada Inc. / SJ STRATEGIC INVESTMENTS LLC - NONE Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Tribute Pharmaceuticals Canada Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 858557 10 1 (CUSIP Number) John M. Gregory, SJ Strateguic Investments, LLC 340 Martin Luther King, Jr. Blvd. Suite 200 Bristol, Tennessee 37620 Phone : (42
March 4, 2015	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 26, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisdiction of i
March 3, 2015	EX-99.1	Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results -4th quarter Revenue up 70.5% and EBITDA up 217% over comparative periods- Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results -4th quarter Revenue up 70.5% and EBITDA up 217% over comparative periods- MILTON, ONTARIO - March 3, 2015 - Tribute Pharmaceuticals Canada Inc. (TSXV:TRX or OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a prim
March 3, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 3, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisdiction of incor
February 27, 2015	SC 13D/A	TBUFF / Tribute Pharmaceuticals Canada Inc. / SJ STRATEGIC INVESTMENTS LLC - NONE Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Tribute Pharmaceuticals Canada Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 858557 10 1 (CUSIP Number) John M. Gregory, SJ Strateguic Investments, LLC 340 MARTIN LUTHER KING, JR. BLVD. SUITE 200 BRISTOL, Tennessee 37620 Phone : (42
February 2, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 27, 2015 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisdiction of in
February 2, 2015	EX-10.2	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 1st day of January, 2015 B E T W E E N : TRIBUTE PHARMACEUTICALS CANADA INC., a corporation organized under the laws of the Province of Ontario, (hereinafter referred to as the "Corporation") - and - SCOTT LANGILLE, of the Town of Guelph, in the Province of Ontario, (hereinafter referred to as the "Executive") RECITALS: WHER
February 2, 2015	EX-10.1	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 1st day of January, 2015 B E T W E E N : TRIBUTE PHARMACEUTICALS CANADA INC., a corporation organized under the laws of the Province of Ontario, (hereinafter referred to as the "Corporation") - and - ROB HARRIS, of the Town of Milton, in the Province of Ontario, (hereinafter referred to as the "Executive") RECITALS: WHEREAS:
January 27, 2015	EX-99.1	Tribute Pharmaceuticals Provides Update of 2014 Revenues; Anticipates Fourth Quarter Revenue Growth in excess of 60% and Full Year Revenue Growth of greater than 20% Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Provides Update of 2014 Revenues; Anticipates Fourth Quarter Revenue Growth in excess of 60% and Full Year Revenue Growth of greater than 20% MILTON, ONTARIO - (Marketwired – January 27, 2015) - Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX Venture: TRX) ("Tribute" or the "Company"), a specialt
January 27, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 27, 2015 Tribute Pharmaceuticals Canada Inc. (Exact Name of Registrant as Specified in its Charter) Ontario, Canada 001-31198 Not Applicable (State or Incorporation) (Commissi
December 9, 2014	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 2, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 000-31198 Not Applicable (State or other jurisdiction of i
December 9, 2014	EX-2.1	ASSET PURCHASE AGREEMENT NOVARTIS PHARMA AG NOVARTIS AG TRIBUTE PHARMACEUTICALS CANADA INC. Exhibit 2.1 Executed copy CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY TRIBUTE PHARMACEUTICALS CANADA INC. Portions herein identified by [**] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. ASSET PURCHASE AGR
December 9, 2014	EX-2.2	LICENSE AGREEMENT NOVARTIS AG NOVARTIS PHARMA AG NOVARTIS PHARMACEUTICALS CANADA INC. TRIBUTE PHARMACEUTICALS CANADA INC. Exhibit 2.2 Executed copy CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY TRIBUTE PHARMACEUTICALS CANADA INC. Portions herein identified by [**] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT
November 10, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 001-31198 Not Applicable (State or other jurisdiction of i
November 10, 2014	EX-99.1	Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014 EXHIBIT 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014 MILTON, ONTARIO - (Marketwired – November 10, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX Venture: TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, develo
November 5, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 001-31198 Not Applicable (State or other jurisdiction of in
November 5, 2014	EX-99.1	Tribute Pharmaceuticals Receives Uracyst® Patent in Europe Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Receives Uracyst® Patent in Europe MILTON, ONTARIO - (Marketwire – October 30, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX Venture: TRX) ("Tribute" or the "Company"), today announced that it has received a patent approval from the European Patent Office (“EPO”) for intellectual proper
October 8, 2014	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 2, 2014 Tribute Pharmaceuticals Canada Inc. (Exact Name of Registrant as Specified in its Charter) Ontario, Canada 001-31198 Not Applicable (State or Incorporation) (Commissio
October 8, 2014	EX-2.1	ASSET PURCHASE AGREEMENT NOVARTIS PHARMA AG NOVARTIS AG TRIBUTE PHARMACEUTICALS CANADA INC. Exhibit 2.1 ASSET PURCHASE AGREEMENT between NOVARTIS PHARMA AG NOVARTIS AG AND TRIBUTE PHARMACEUTICALS CANADA INC. Executed copy Table of Contents 1. Definitions and Interpretation 3 2. Sale and Transfer of Assets 8 3. Grant of Licenses 10 4. Assumed Liabilities and Excluded Liabilities 10 5. Obligations of the Purchaser 10 6. Transition Services provided by Novartis 11 7. Maintenance of Marketin
October 8, 2014	EX-2.2	LICENSE AGREEMENT NOVARTIS AG NOVARTIS PHARMA AG NOVARTIS PHARMACEUTICALS CANADA INC. TRIBUTE PHARMACEUTICALS CANADA INC. Exhibit 2.2 LICENSE AGREEMENT between NOVARTIS AG NOVARTIS PHARMA AG NOVARTIS PHARMACEUTICALS CANADA INC. and TRIBUTE PHARMACEUTICALS CANADA INC. 1 Executed copy Table of Contents 1.. DEFINITIONS AND INTERPRETATION 3 2. LICENSE 5 3. TRANSFER OF LICENSED ASSETS 5 4. APPLICATION AND USE OF LICENSED TRADEMARKS 5 5. QUALITY CONTROL AND APPROVAL PROCEDURES 6 6. NOVARTIS NAME AND LOGO 6 7. FURTHER OBLIG
October 8, 2014	EX-99.1	Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal®, Fiorinal® C, Visken® and Viskazide® Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal®, Fiorinal® C, Visken® and Viskazide® ● Tribute expects positive EBITDA in Q4 2014 and Fiscal 2015 MILTON, ONTARIO-(Marketwire October 2, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX Venture: TRX) ("Tribute" or the "Company"), is ple
October 7, 2014	8-K/A	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 1, 2014 Tribute Pharmaceuticals Canada Inc. (Exact Name of Registrant as Specified in its Charter) Ontario, Canada 001-31198 Not Applicable (State or Incorporation) (Commiss
September 25, 2014	EX-99.1	Tribute Pharmaceuticals Receives 4th Uracyst® Patent in United States Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Receives 4th Uracyst® Patent in United States MILTON, ONTARIO — September 25, 2014 - MILTON, ONTARIO- (Marketwire) - Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX Venture: TRX) ("Tribute" or the "Company"), today announced that it has received an additional patent from the U.S. Patent and Trade
September 25, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 001-31198 Not Applicable (State or other jurisdiction of
August 11, 2014	EX-99.1	Tribute Pharmaceuticals Reports Solid Second Quarter 2014 Results EXHIBIT 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc Tribute Pharmaceuticals Reports Solid Second Quarter 2014 Results MILTON, ONTARIO - (Marketwired - August 11, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX-V: TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of hea
August 11, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commissi
August 6, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 001-31198 Not Applicable (State or other jurisdiction of inco
August 6, 2014	EX-99.1	Tribute Pharmaceuticals Schedules Second Quarter 2014 Financial Results Conference Call EXHIBIT 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc Tribute Pharmaceuticals Schedules Second Quarter 2014 Financial Results Conference Call MILTON, ONTARIO - (Marketwired - Aug 6, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX-V:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and
August 6, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commissio
August 1, 2014	F-3	TBUFF / Tribute Pharmaceuticals Canada Inc. F-3 - - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on August 1, 2014 Registration No.
July 17, 2014	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 001-31198 Not Applicable (State or other jurisdiction of inc
June 27, 2014	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 001-31198 Not Applicable (State or other jurisdiction of incor
June 27, 2014	EX-1.1	UNDERWRITING AGREEMENT Exhibit 1.1 UNDERWRITING AGREEMENT June 25, 2014 Tribute Pharmaceuticals Canada Inc. 151 Steeles Avenue East Milton, Ontario L9T 1Y1 Attention: Rob Harris, President and Chief Executive Officer Dear Sir: Based upon and subject to the terms and conditions set out in this agreement (the “Underwriting Agreement”), Dundee Securities Ltd. (the “Lead Underwriter”) and Mackie Research Capital Corporation
May 30, 2014	8-K	Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 001-31198 Not Applicable (State or other jurisdiction of incorpo
May 30, 2014	EX-99.1	1 Exhibit 99.1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
May 30, 2014	EX-99.2	2 Exhibit 99.2 2
May 27, 2014	EX-99.1	Tribute Pharmaceuticals Trading on TSX Venture Exchange Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Trading on TSX Venture Exchange MILTON, ONTARIO-(Marketwired - May 27, 2014) - Tribute Pharmaceuticals Canada Inc. (TRX;TSX.V) (TBUFF;OTCQB) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare product
May 27, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commission
May 23, 2014	EX-99.1	Tribute Pharmaceuticals Receives Approval to List on TSX Venture Exchange Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Receives Approval to List on TSX Venture Exchange MILTON, ONTARIO-(Marketwired - May 23, 2014) - Tribute Pharmaceuticals Canada Inc. (TBUFF;OTCQB) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare p
May 23, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commission
May 15, 2014	EX-99.1	Tribute Pharmaceuticals Reports First Quarter 2014 Results & Schedules First Quarter 2014 Conference Call EXHIBIT 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Reports First Quarter 2014 Results & Schedules First Quarter 2014 Conference Call MILTON, ONTARIO-(Marketwired - May 15, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, developme
May 15, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commission
May 13, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commission
May 13, 2014	EX-99.1	Tribute Pharmaceuticals and Faes Farma Announce Exclusive License Agreement in Canada for Bilastine, a New Treatment Option in the $120 million Allergic Rhinitis and Urticaria Market EXHIBIT 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals and Faes Farma Announce Exclusive License Agreement in Canada for Bilastine, a New Treatment Option in the $120 million Allergic Rhinitis and Urticaria Market MILTON, ONTARIO and MADRID, SPAIN— (Marketwired – May 13, 2014) - Tribute Pharmaceuticals Canada Inc. (“Tribute”) (OTCQB:TBUFF)(a Canadian special
May 8, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commission F
May 8, 2014	EX-99.1	Tribute Pharmaceuticals Schedules First Quarter 2014 Financial Results Conference Call EXHIBIT 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Schedules First Quarter 2014 Financial Results Conference Call MILTON, ONTARIO-(Marketwired - May 8, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the "Company"), a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of heal
April 1, 2014	EX-99.1	Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future Growth EXHIBIT 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future Growth MILTON, ONTARIO-(Marketwired - March 31, 2014) - Tribute Pharmaceuticals Canada Inc. (TBUFF) ("Tribute" or the "Company"), a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion o
April 1, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commis
March 31, 2014	10-K	Tribute Pharmaceuticals Canada ANNUAL REPORT (Annual Report) tbuff10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED: DECEMBER 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0- 31198 TRIBUTE PH
March 3, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2014 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commission
March 3, 2014	EX-99.1	Tribute Pharmaceuticals Appoints JSB-Partners to Lead Partnership Discussions on Bezalip® SR for the US Market Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Appoints JSB-Partners to Lead Partnership Discussions on Bezalip® SR for the US Market MILTON, ONTARIO CANADA - (Marketwired - March 3, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licen
February 11, 2014	EX-4.1	PROMISSORY NOTE Exhibit 4.1 PROMISSORY NOTE $2,000,000.00 February 4, 2014 FOR VALUE RECEIVED and pursuant to the terms of this Promissory Note (this “Note”), the undersigned, TRIBUTE PHARMACEUTICALS CANADA INC., a Delaware corporation (“Borrower”), having an address at 15770 Dallas Parkway, Suite 1290, Dallas, TX 75248, promises to pay to the order of SWK FUNDING LLC, a Delaware limited liability company as agen
February 11, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2014 (February 6, 2014) Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other j
February 11, 2014	EX-4.2	Void after 5:00 p.m. (Toronto time) on the 4th day of February, 2021 Exhibit 4.2 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE JUNE 5. THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF TH
December 20, 2013	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commis
December 20, 2013	EX-99.1	CAMBIA® Update from Tribute Pharmaceuticals EX-99.1 2 tbuff991.htm PRESS RELEASE Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. CAMBIA® Update from Tribute Pharmaceuticals Milton, Ontario, Canada, December 20, 2013 – Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthc
November 29, 2013	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commis
November 29, 2013	EX-99.1	Tribute Pharmaceuticals Announces Solid Growth in Third Quarter 2013 and Bezalip US IND Cleared by FDA Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Announces Solid Growth in Third Quarter 2013 and Bezalip US IND Cleared by FDA Milton, Ontario, Canada, November 14, 2013 – Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the “Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion o
November 14, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commis
November 14, 2013	424B3	TRIBUTE PHARMACEUTICALS CANADA INC. 22,725,000 Common Shares Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration File No. 333-187927 Prospectus Supplement No. 2 TRIBUTE PHARMACEUTICALS CANADA INC. 22,725,000 Common Shares This prospectus supplement no. 2 supplements the prospectus dated June 14, 2013, as supplemented by prospectus supplement no. 1 dated August 14, 2013, which forms a part of our registration statement on Form S-1 (Registration Fil
November 14, 2013	EX-99.1	Tribute Pharmaceuticals Announces Solid Growth in Third Quarter 2013 and Bezalip US IND Cleared by FDA Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Announces Solid Growth in Third Quarter 2013 and Bezalip US IND Cleared by FDA Milton, Ontario, Canada, November 14, 2013 – Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or "the Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion o
November 12, 2013	EX-99.1	TRIBUTE PHARMA’S Investigational New Drug Application for Bezalip® SR Cleared by the US Food and Drug Administration EXHIBIT 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. TRIBUTE PHARMA’S Investigational New Drug Application for Bezalip® SR Cleared by the US Food and Drug Administration MILTON, ONTARIO - (Marketwire) – November 11, 2013 - Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, lic
November 12, 2013	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commis
August 14, 2013	EX-10.1	CREDIT AGREEMENT dated as of August 8, 2013 TRIBUTE PHARMACEUTICALS CANADA INC. as Borrower, THE LENDERS PARTY HERETO, as Lenders, SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner EXHIBIT 10.1 EXECUTION VERSION CREDIT AGREEMENT dated as of August 8, 2013 among TRIBUTE PHARMACEUTICALS CANADA INC. as Borrower, THE LENDERS PARTY HERETO, as Lenders, and SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITI
August 14, 2013	EX-10.3	INTELLECTUAL PROPERTY SECURITY AGREEMENT EXHIBIT 10.3 INTELLECTUAL PROPERTY SECURITY AGREEMENT INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of August 8, 2013 (this “Agreement”), made by TRIBUTE PHARMACEUTICALS CANADA INC., a corporation incorporated under the laws of Ontario, Canada (“Borrower”), in favor of SWK FUNDING LLC, a Delaware limited liability company, as collateral agent for lenders party to the Credit Agreement (as defi
August 14, 2013	424B3	TRIBUTE PHARMACEUTICALS CANADA INC. 22,725,000 Common Shares Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration File No. 333-187927 Prospectus Supplement No. 1 TRIBUTE PHARMACEUTICALS CANADA INC. 22,725,000 Common Shares This prospectus supplement no. 1 supplements the prospectus dated June 14, 2013, which forms a part of our registration statement on Form S-1 (Registration File No. 333-187927). This prospectus supplement is being filed to update
August 14, 2013	EX-10.2	GUARANTEE AND COLLATERAL AGREEMENT dated as of August 8, 2013 TRIBUTE PHARMACEUTICALS CANADA INC. as Grantor, SWK FUNDING LLC, as Agent EXHIBIT 10.2 GUARANTEE AND COLLATERAL AGREEMENT dated as of August 8, 2013 among TRIBUTE PHARMACEUTICALS CANADA INC. as Grantor, and SWK FUNDING LLC, as Agent [Tribute] Guarantee and Collateral Agreement 1 GUARANTEE AND COLLATERAL AGREEMENT Guarantee and Collateral Agreement, dated as of August 8, 2013 (this “Agreement”), made by each signatory hereto (together with any other Person that becomes a
August 14, 2013	EX-4.2	Void after 5:00 p.m. (Toronto time) on the 8th day of August, 2020. EXHIBIT 4.1 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE DECEMBER 9, 2013. THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BEN
August 14, 2013	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2013 (August 8, 2013) Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada (State or other jurisdiction of incorporatio
August 14, 2013	EX-4.1	PROMISSORY NOTE Exhibit 4.1 PROMISSORY NOTE $6,000,000.00 August 8, 2013 FOR VALUE RECEIVED and pursuant to the terms of this Promissory Note (this “Note”), the undersigned, TRIBUTE PHARMACEUTICALS CANADA INC., an Ontario corporation (“Borrower”), having an address at 151 Steeles Avenue East, Milton, Ontario, Canada, 19T 1Y1, promises to pay to the order of SWK FUNDING LLC, a Delaware limited liability company as
August 9, 2013	EX-99.1	Tribute Pharmaceuticals Announces Double Digit Growth in Second Quarter 2013 Exhibit 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Announces Double Digit Growth in Second Quarter 2013 Milton, Ontario, Canada, August 9, 2013 – Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or "the Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare pro
August 9, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction (Commissio
June 26, 2013	8-K	Submission of Matters to a Vote of Security Holders - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada (State or other jurisdiction of incorporation) 0-31198 (Commiss
June 24, 2013	424B3	TRIBUTE PHARMACEUTICALS CANADA INC. 22,725,000 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-187927 Prospectus TRIBUTE PHARMACEUTICALS CANADA INC. 22,725,000 Common Shares This prospectus relates solely to the resale or other disposition by the selling shareholders identified in this prospectus of up to an aggregate of 22,725,000 common shares, consisting of (i) 11,362,500 common shares and (ii) an aggregate of 11,362,500 common shares
June 17, 2013	CORRESP	- TRIBUTE PHARMACEUTICALS CANADA INC. 151 Steeles Ave E, Milton, Ontario, L9T 1Y1 Canada June 17, 2013 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: Tribute Pharmaceuticals Canada Inc. Registration Statement on Form S-1 File No. 333-187927 Ladies and Gentlemen: T
June 14, 2013	S-1/A	- AMENDMENT NO. 2 As filed with the Securities and Exchange Commission on June 14, 2013 Registration No.
June 6, 2013	DEF 14A	- DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)
May 22, 2013	CORRESP	- HERRICK new york newark princeton Daniel A. Etna Partner Direct Tel: 212.592.1557 Direct Fax: 212.545.3322 Email: [email protected] May 20, 2013 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: Tribute Pharmaceuticals Canada Inc. Registration Statement on Form
May 22, 2013	S-1/A	- As filed with the Securities and Exchange Commission on May 21 , 2013 Registration No.
May 14, 2013	EX-99.1	Tribute Pharmaceuticals Announces Double Digit Growth in First Quarter 2013 EXHIBIT 99.1 Press Release Source: Tribute Pharmaceuticals Canada Inc. Tribute Pharmaceuticals Announces Double Digit Growth in First Quarter 2013 Milton, Ontario, Canada, May 14, 2013 – Tribute Pharmaceuticals Canada Inc. (formerly Stellar Pharmaceuticals Inc.) (OTCQB:TBUFF;) ("Tribute" or "the Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, devel
May 14, 2013	8-K	Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction of incorpora
April 12, 2013	8-K/A	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 3) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 1, 2011 Tribute Pharmaceuticals Canada Inc. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Ontario, Canada (STATE OR OTHER JURISDICTION OF INCORPO
April 12, 2013	S-1	Registration Statement - As filed with the Securities and Exchange Commission on April 12, 2013 Registration No.
April 12, 2013	EX-10.2	- EXECUTIVE EMPLOYMENT AGREEMENT EXHIBIT 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 1st day of December, 2011 B E T W E E N : STELLAR PHARMACEUTICALS INC., a corporation organized under the laws of the Province of Ontario, (hereinafter referred to as the "Corporation") - and - SCOTT M. LANGILLE, of the Town of Elora, in the Province of Ontario, (hereinafter referred to as the "Executive") RECITALS: WHEREAS:
April 12, 2013	EX-1.1	EXECUTIVE EMPLOYMENT AGREEMENT EXHIBIT 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 1st day of December, 2011 B E T W E E N : STELLAR PHARMACEUTICALS INC., a corporation organized under the laws of the Province of Ontario, (hereinafter referred to as the "Corporation") - and - ROB HARRIS, of the Town of Milton, in the Province of Ontario, (hereinafter referred to as the "Executive") RECITALS: WHEREAS: A. Th
March 21, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction of incorpo
March 21, 2013	EX-99.1	Tribute Pharmaceuticals Reports 2012 Year-End Results with Strong Revenue Growth Exhibit 99.1 Tribute Pharmaceuticals Reports 2012 Year-End Results with Strong Revenue Growth Milton, Ontario, Canada, March 20, 2013 – Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF; OTCBB:TBUFF) ("Tribute" or "the Company"), a Canadian specialty pharmaceutical company, today announced financial results for the year ended December 31, 2012. In this press release, all dollar amounts are expresse
March 14, 2013	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2013 (March 11, 2013) Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisd
March 14, 2013	EX-10.1	- SECURITIES PURCHASE AGREEMENT EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March , 2013, between TRIBUTE PHARMACEUTICALS CANADA INC., an Ontario corporation (f/k/a Stellar Pharmaceuticals Inc.) (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers
March 14, 2013	EX-10.3	[SERIES A/B] COMMON STOCK PURCHASE WARRANT TRIBUTE PHARMACEUTICALS CANADA INC. Warrant Shares: [_______] Initial Exercise Date: March ____, 2013 EXHIBIT 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R
March 14, 2013	EX-10.2	- REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March , 2013, between TRIBUTE PHARMACEUTICALS CANADA INC. an Ontario corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securitie
March 11, 2013	SC 13D/A	TBUFF / Tribute Pharmaceuticals Canada Inc. / SJ STRATEGIC INVESTMENTS LLC - TRIBUTE PHARMACEUTICALS CANADA INC. 13DA MARCH 4, 2013 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* TRIBUTE PHARMACEUTICALS CANADA INC. (Name of Issuer) Common Shares (Title of Class of Securities) 858557 10 1 (CUSIP Number) Lori B. Metrock, Esq. Baker, Donelson, Bearman, Caldwell & Berkowitz, PC 211 Commerce Street, Suite 800 Nashville, Tennessee 3720
March 8, 2013	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdictionof incorpora
March 8, 2013	EX-10.2	REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 5, 2013, between TRIBUTE PHARMACEUTICALS CANADA INC. an Ontario corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securiti
March 8, 2013	EX-10.3	[SERIES A/B] COMMON STOCK PURCHASE WARRANT TRIBUTE PHARMACEUTICALS CANADA INC. Warrant Shares: [_______] Initial Exercise Date: March 5, 2013 EXHIBIT 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R
March 8, 2013	EX-10.1	SECURITIES PURCHASE AGREEMENT EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 5, 2013, between TRIBUTE PHARMACEUTICALS CANADA INC., an Ontario corporation (f/k/a Stellar Pharmaceuticals Inc.) (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchaser
March 5, 2013	EX-10.1	- SECURITIES PURCHASE AGREEMENT EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 27, 2013, between TRIBUTE PHARMACEUTICALS CANADA INC., an Ontario corporation (f/k/a Stellar Pharmaceuticals Inc.) (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purch
March 5, 2013	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities 8-K 1 tbuff8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2013 Tribute Pharmaceuticals Canada Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (St
March 5, 2013	EX-10.2	REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.2 EXHIBIT A REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 27, 2013, between TRIBUTE PHARMACEUTICALS CANADA INC. an Ontario corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant t
March 5, 2013	EX-10.3	[SERIES A/B] COMMON STOCK PURCHASE WARRANT TRIBUTE PHARMACEUTICALS CANADA INC. EXHIBIT 10.3 EXHIBIT C NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E
March 5, 2013	EX-99.1	- PRESS RELEASE EXHIBIT 99.1 1 2 3
February 11, 2013	EX-10.4	AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EXHIBIT 10.4 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made effective as of the 1st day of December, 2011. B E T W E E N : STELLAR PHARMACEUTICALS INC., a corporation organized under the laws of the Province of Ontario, (hereinafter referred to as the "Corporation") - and - JANICE M. CLARKE, of the City of Mt. Brydges, in the Province of Ontario, (hereinafter referred to a
February 11, 2013	EX-10.1	EXECUTIVE EMPLOYMENT AGREEMENT EXHIBIT 10.1 CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 1st day of December, 2011 B E T W E E N : STELLAR PHARMACEUTICALS INC., a corporation organized under the laws of the Province of Ontari
February 11, 2013	EX-99.1	TRIBUTE PHARMACEUTICALS CANADA LTD. FINANCIAL STATEMENTS For the year ended June 30, 2011 (Expressed in Canadian dollars) TRIBUTE PHARMACEUTICALS CANADA LTD. FINANCIAL STATEMENTS June 30, 2011 INDEX Page Independent Auditor’s Report 1 Statement of Fi EXHIBIT 99.1 TRIBUTE PHARMACEUTICALS CANADA LTD. FINANCIAL STATEMENTS For the year ended June 30, 2011 (Expressed in Canadian dollars) TRIBUTE PHARMACEUTICALS CANADA LTD. FINANCIAL STATEMENTS June 30, 2011 INDEX Page Independent Auditor’s Report 1 Statement of Financial position 2 Statement of Operations and Comprehensive loss 3 Statement of Changes in Shareholders’ equity 4 Statement of Cash Flow
February 11, 2013	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Other Events - AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 1, 2011 Tribute Pharmaceuticals Canada Inc. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Ontario, Canada (STATE OR OTHER JURISDICTION OF INCORPO
February 11, 2013	EX-99.4	TRIBUTE PHARMA CANADA INC. CONDENSED INTERIM FINANCIAL STATEMENTS For the interim three month and sixth month periods ended September 30, 2011 (Expressed in Canadian dollars) TRIBUTE PHARMA CANADA INC. CONDENSED INTERIM FINANCIAL STATEMENTS September EXHIBIT 99.4 TRIBUTE PHARMA CANADA INC. CONDENSED INTERIM FINANCIAL STATEMENTS For the interim three month and sixth month periods ended September 30, 2011 (Unaudited) (Expressed in Canadian dollars) TRIBUTE PHARMA CANADA INC. CONDENSED INTERIM FINANCIAL STATEMENTS September 30, 2011 INDEX Page Condensed Interim Statements of Financial Position 1 Condensed Interim Statements of Operations and Comp
February 11, 2013	EX-10.2	EXECUTIVE EMPLOYMENT AGREEMENT EXHIBIT 10.2 CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 1st day of December, 2011 B E T W E E N : STELLAR PHARMACEUTICALS INC., a corporation organized under the laws of the Province of Ontari
February 11, 2013	EX-10.6	Page 1 of 2 EXHIBIT 10.6 Page 1 of 2 Page 2 of 2
February 11, 2013	EX-99.3	TRIBUTE PHARMACEUTICALS CANADA LTD. CONDENSED INTERIM FINANCIAL STATEMENTS For the interim three month period ended September 30, 2011 (Unaudited – Prepared by Management) (Expressed in Canadian dollars) TRIBUTE PHARMACEUTICALS CANADA LTD. CONDENSED EXHIBIT 99.3 TRIBUTE PHARMACEUTICALS CANADA LTD. CONDENSED INTERIM FINANCIAL STATEMENTS For the interim three month period ended September 30, 2011 (Unaudited – Prepared by Management) (Expressed in Canadian dollars) TRIBUTE PHARMACEUTICALS CANADA LTD. CONDENSED INTERIM FINANCIAL STATEMENTS September30, 2011 INDEX Page Condensed Interim Statements of Financial position 2 Condensed Interim Statemen
February 11, 2013	EX-10.3	CONSULTING AGREEMENT EXHIBIT 10.3 CONSULTING AGREEMENT THIS AGREEMENT made as of the 1st day of December, 2011. B E T W E E N : STELLAR PHARMACEUTICALS INC. (the "Corporation") - and - LMT FINANCIAL INC. ("LMT") WHEREAS the board of directors retained Arnold Tenney, through his consulting company LMT Financial Inc., ("LMT") as an independent consultant to the Corporation to act as Interim President and Interim Chief E
February 11, 2013	EX-99.5	UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS EXHIBIT 99.5 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The following unaudited pro forma condensed consolidated financial statements is presented to illustrate the estimated effects of the acquisition by Tribute Pharmaceuticals Canada Inc. (formerly Stellar Pharmaceuticals Inc.) (“Stellar” or the “Company”) of Tribute Pharma Canada Inc. and Tribute Pharmaceuticals Canada Ltd.
February 11, 2013	EX-99.2	TRIBUTE PHARMA CANADA INC. FINANCIAL STATEMENTS For the years ended March 31, 2011 and 2010 (Expressed in Canadian dollars) TRIBUTE PHARMA CANADA INC. FINANCIAL STATEMENTS March 31, 2011 and 2010 EXHIBIT 99.2 TRIBUTE PHARMA CANADA INC. FINANCIAL STATEMENTS For the years ended March 31, 2011 and 2010 (Expressed in Canadian dollars) TRIBUTE PHARMA CANADA INC. FINANCIAL STATEMENTS March 31, 2011 and 2010 INDEX Page Independent Auditor’s Report 1 Statements of Financial Position 2 Statements of Operations and Comprehensive loss 3 Statements of Changes in Shareholders’ equity 4 Statements of Ca
February 11, 2013	EX-4.1	Page 1 of 4 Page 2 of 4 Page 3 of 4 Page 4 of 4 EXHIBIT 4.1 Page 1 of 4 Page 2 of 4 Page 3 of 4 Page 4 of 4
February 11, 2013	EX-2.1	SHARE PURCHASE AGREEMENT STELLAR PHARMACEUTICALS INC. ELORA FINANCIAL MANAGEMENT INC. MARY-ANN HARRIS ROB HARRIS SCOTT LANGILLE EXHIBIT 2.1 SHARE PURCHASE AGREEMENT BETWEEN STELLAR PHARMACEUTICALS INC. and ELORA FINANCIAL MANAGEMENT INC. and MARY-ANN HARRIS and ROB HARRIS and SCOTT LANGILLE 1 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 4 ARTICLE 2 PURCHASE AND SALE 12 ARTICLE 3 REPRESENTATIONS AND WARRANTIES 14 ARTICLE 4 COVENANTS 44 ARTICLE 5 CONDITIONS OF CLOSING 47 ARTICLE 6 CLOSING ARRANGEMENTS 41 ARTICLE 7 INDEMNIFICAT
February 11, 2013	EX-10.5	Page 1 of 6 EXHIBIT 10.5 Page 1 of 6 Page 2 of 6 Page 3 of 6 Page 4 of 6 Page 5 of 6 Page 6 of 6
January 2, 2013	EX-99.2	Stellar Pharmaceuticals Announces Name & Ticker Change to Tribute Pharmaceuticals Canada Inc. and ‘TBUFF’; Issues Letter to Shareholders EXHIBIT 99.2 Press Release Source: Stellar Pharmaceuticals Inc. Stellar Pharmaceuticals Announces Name & Ticker Change to Tribute Pharmaceuticals Canada Inc. and ‘TBUFF’; Issues Letter to Shareholders Milton, Ontario, Canada, January 2, 2013 – Stellar Pharmaceuticals Inc. (OTCQB: SLXCF) (OTCBB:SLXCF) (OTCQB: TBUFF) (OTCBB: TBUFF) ("Stellar" or "the Company"), a Canadian specialty pharmaceutical co
January 2, 2013	8-K	Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December26, 2012 Tribute Pharmaceuticals Canada Inc. (Exact name of Registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or other jurisdiction of inco
January 2, 2013	EX-3.1	18 EXHIBIT 3.1 18
January 2, 2013	EX-99.1	Stellar Pharmaceuticals Inc., 151 Steeles Avenue East, Milton, Ontario, Canada, L9T 1Y1 EXHIBIT 99.1 December 24, 2012 Dear Fellow Stellar Shareholders, We are pleased to conclude 2012 having reported strong revenue growth for the first nine months of the year and having transformed Stellar Pharmaceuticals, Inc. (the “Company”) into a rapidly growing Canadian specialty pharmaceutical company with an expanding product portfolio, a national sales force, and distribution channels with c
November 13, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (
November 13, 2012	EX-99.1	Stellar Pharmaceuticals Shows Strong Third Quarter Revenue Growth to $3.2 Million EXHIBIT 99.1 Press Release Source: Stellar Pharmaceuticals Inc. Stellar Pharmaceuticals Shows Strong Third Quarter Revenue Growth to $3.2 Million Milton, Ontario, Canada, November 13, 2012 – Stellar Pharmaceuticals Inc. (OTCQB:SLXCF; OTCBB:SLXCF) ("Stellar" or "the Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthc
October 9, 2012	EX-99.1	Stellar Pharmaceuticals Launches New Migraine Treatment, CAMBIA®, in $150 Million Canadian Prescription Migraine Market Press Release Source: Stellar Pharmaceuticals Inc. Stellar Pharmaceuticals Launches New Migraine Treatment, CAMBIA®, in $150 Million Canadian Prescription Migraine Market · Potential to gain a significant proportion of Canadian migraine market · CAMBIA® is the only available prescription non-steroidal anti-inflammatory drug (“NSAID”) available with an indication for the acute treatment of migraine
October 9, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.
August 31, 2012	SC 13D/A	TBUFF / Tribute Pharmaceuticals Canada Inc. / SJ STRATEGIC INVESTMENTS LLC - STELLAR PHARMACEUTICALS, INC. FORM 13DA AUGUST 27, 2012 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* STELLAR PHARMACEUTICALS, INC. (Name of Issuer) Common Shares (Title of Class of Securities) 858557 10 1 (CUSIP Number) Linda M. Crouch-McCreadie, Esq. Baker, Donelson, Bearman, Caldwell & Berkowitz, PC 100 Medtech Parkway Johnson City, TN 37604 (423) 928
August 27, 2012	EX-99.1	Stellar Pharmaceuticals enters into a partnership with Pfizer Canada Inc. to promote Gelfoam® in Canada - Stellar to further expand and strengthen its Specialty Care Products business with addition of Gelfoam® (absorbable gelatin sponge, USP) promoti Press Release Source: Stellar Pharmaceuticals Inc. Stellar Pharmaceuticals enters into a partnership with Pfizer Canada Inc. to promote Gelfoam® in Canada - Stellar to further expand and strengthen its Specialty Care Products business with addition of Gelfoam® (absorbable gelatin sponge, USP) promotion MILTON, ONTARIO - (MARKET WIRE) - August 23, 2012 - Stellar Pharmaceuticals Inc. ("Stellar")(OTC
August 27, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.R
August 14, 2012	EX-99.1	Stellar Pharmaceuticals Reports Second Quarter and First Half 2012 Financial Results Press Release Source: Stellar Pharmaceuticals Inc. Stellar Pharmaceuticals Reports Second Quarter and First Half 2012 Financial Results Total revenues and gross profits up due to strong Licensed Domestic Product Net Sales MILTON, ONTARIO – (MARKET WIRE) – August 14, 2012 – Stellar Pharmaceuticals Inc. (OTCQB:SLXCF; OTCBB:SLXCF) ("Stellar" or "the Company"), an emerging specialty pharmaceutical com
August 14, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.
June 20, 2012	EX-99.1	Stellar Pharmaceuticals acquires the exclusive rights to Collatamp G® in Canada - Stellar strengthens its Specialty Care Products business with Collatamp G® (gentamicin impregnated sponge) acquisition MILTON, ONTARIO -- (MARKET WIRE) -- June 20, 2012 Press Release Source: Stellar Pharmaceuticals Inc. Stellar Pharmaceuticals acquires the exclusive rights to Collatamp G® in Canada - Stellar strengthens its Specialty Care Products business with Collatamp G® (gentamicin impregnated sponge) acquisition MILTON, ONTARIO - (MARKET WIRE) - June 20, 2012 - Stellar Pharmaceuticals Inc. ("Stellar")(OTCQB: SLXCF)(OTCBB: SLXCF)(PINKSHEETS: SLXCF) today anno
June 20, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.R.
May 18, 2012	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 11, 2012 Stellar Pharmaceuticals Inc. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Ontario, Canada (STATE OR OTHER JURISDICTION OF INCORPORATION) 0-31198 Not Applicable
May 15, 2012	EX-99.1	Stellar Pharmaceuticals Reports First Quarter 2012 Financial Results Press Release Source: Stellar Pharmaceuticals Inc. Stellar Pharmaceuticals Reports First Quarter 2012 Financial Results Company outperforms growth targets as a result of expanded product lines MILTON, ONTARIO – (MARKET WIRE) – May 15, 2012 – Stellar Pharmaceuticals Inc. (OTCQB:SLXCF; OTCBB:SLXCF) ("Stellar" or "the Company"), an emerging specialty pharmaceutical company with a primary focus on the
May 15, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.R.S
April 12, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION\ WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 5, 2012 Stellar Pharmaceuticals Inc. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Ontario, Canada (STATE OR OTHER JURISDICTION OF INCORPORATION) 0-31198 (COMMISSION F
April 12, 2012	EX-4.1	[Remainder of Page Intentionally Left Blank; Signature Page Follows] Exhibit 4.1 Extension of Expiry Time (this “Extension”), dated as of April 5, 2012 (“Effective Date”) by Stellar Pharmaceuticals Inc., organized under the laws of Ontario (the “Company”). Whereas, the Company issued to the undersigned holder (“Holder”) warrants pursuant to the following warrant certificates (collectively, the “Warrants”): ● Series 1 Warrant Certificate Number , representing the ri
April 3, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.R
April 3, 2012	EX-99.1	Stellar Pharmaceuticals Strong Product Sales in 2011; Builds for the Future Press Release Source: Stellar Pharmaceuticals Inc. Stellar Pharmaceuticals Strong Product Sales in 2011; Builds for the Future MILTON ONTARIO — APRIL 2, 2012 - Stellar Pharmaceuticals Inc. (OTCQB:SLXCF; OTCBB:SLXCF; PINK SHEETS: SLXCF) ("Stellar" or "the Company"), an emerging specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthca
April 3, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.R.
April 3, 2012	EX-99.1	Shareholder Early Warning News Release Press Release Source: Stellar Pharmaceuticals Inc. Shareholder Early Warning News Release LONDON, ONTARIO March 29, 2012 – Robert Harris of 5590 Steeles Avenue West, Milton, Ontario, announced his acquisition of 3,575,000 common shares and 1,034,276 options of Stellar Pharmaceuticals Inc. ("Stellar"). The common shares were issued to Mr. Harris in connection with the acquisition by Stellar of Trib
April 2, 2012	NT 10-K	- LATE FILING NOTICE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): þ Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2011 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Fo
March 16, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.R
March 16, 2012	EX-99.1	Source: Stellar Pharmaceuticals Inc. - EXHIBIT 99.1 Press Release Source: Stellar Pharmaceuticals Inc. Health Canada Approves CAMBIA® for the Treatment of Acute Migraine · New treatment approved for Canadian patients suffering from acute migraine · Cambia®, the only available prescription NSAID with an indication for the acute treatment of migraine attacks with or without aura in adults is approved by Health Canada Milton, Ontario, Canada, March 16
February 9, 2012	8-K/A	Financial Statements and Exhibits - AMENDED CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 1, 2011 Stellar Pharmaceuticals Inc. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Ontario, Canada (STATE OR OTHER JURISDICTION OF INCORPORATION)
January 26, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I
January 26, 2012	EX-99.1	Source: Stellar Pharmaceuticals Inc. Press Release Source: Stellar Pharmaceuticals Inc. Stellar Pharmaceuticals Receives 2nd Uracyst® Patent in United States of America LONDON, ONTARIO — January 26, 2012 - Stellar Pharmaceuticals Inc. (OTCQB:SLXCF; OTCBB:SLXCF; PINK SHEETS: SLXCF) ("Stellar" or "the Company"), today announced that it has received another patent from the U.S. Patent and Trademark Office (USPTO) for intellectual proper
January 3, 2012	EX-99.1	Source: Stellar Pharmaceuticals Inc. & Tribute Pharmaceuticals EXHIBIT 99.1 Press Release For Immediate Release Source: Stellar Pharmaceuticals Inc. & Tribute Pharmaceuticals MILTON, ON, January 3, 2011 – Stellar Pharmaceuticals Inc. ("Stellar") (OTCQB:SLXCF; OTCBB:SLXCF; PINK SHEETS: SLXCF), a Canadian public company) announced today that Murray Roach has joined the company as Vice President of Sales. Mr. Roach has nearly 20 years of pharmaceutical sales and
January 3, 2012	EX-99.1	APRICUS BIOSCIENCES AND STELLAR PHARMACEUTICALS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT IN CANADA FOR THE COMMERCIALIZATION OF MYCOVA™ FOR ONYCHOMYCOSIS Apricus Bio Can Receive Up To Approximately $8 Million (Canadian) Plus Tiered Double Digit Royalties EXHIBIT 99.1 APRICUS BIOSCIENCES AND STELLAR PHARMACEUTICALS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT IN CANADA FOR THE COMMERCIALIZATION OF MYCOVA™ FOR ONYCHOMYCOSIS Apricus Bio Can Receive Up To Approximately $8 Million (Canadian) Plus Tiered Double Digit Royalties Under Multi-year Agreement Stellar Pharma Strengthens Its Dermatology Business In Canada With Its Second Prescription Product, MycoVa™ S
January 3, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.
January 3, 2012	EX-99.1	Source: Stellar Pharmaceuticals Inc. & Tribute Pharmaceuticals EXHIBIT 99.1 Press Release For Immediate Release Source: Stellar Pharmaceuticals Inc. & Tribute Pharmaceuticals MILTON, ON, January 3, 2011 – Stellar Pharmaceuticals Inc. ("Stellar") (OTCQB:SLXCF; OTCBB:SLXCF; PINK SHEETS: SLXCF), a Canadian public company) announced today that the Company intends host a conference call at 4:00 p.m. Eastern Time on Tuesday, January 3, 2012 to discuss the details o
January 3, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.
January 3, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2012 Stellar Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 0-31198 Not Applicable (State or Other Jurisdiction (Commission (I.

TBUFF / Tribute Pharmaceuticals Canada Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)